Douglas Lane & Associates LLC increased its holdings in shares of Moderna, Inc. (NASDAQ:MRNA – Get Rating) by 56.8% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 113,362 shares of the company's stock after purchasing an additional 41,081 shares during the quarter. Douglas Lane & Associates LLC's holdings in Moderna were worth $16,194,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Standard Family Office LLC purchased a new position in Moderna in the 4th quarter worth approximately $25,000. Lake Point Wealth Management purchased a new position in Moderna in the 4th quarter worth approximately $27,000. IFS Advisors LLC purchased a new position in Moderna in the 4th quarter worth approximately $27,000. Bivin & Associates Inc. purchased a new position in shares of Moderna during the 4th quarter valued at approximately $29,000. Finally, Johnson Financial Group Inc. purchased a new position in shares of Moderna during the 4th quarter valued at approximately $32,000. Institutional investors and hedge funds own 60.76% of the company's stock.
Get Moderna alerts:Moderna Price Performance
Shares of MRNA opened at $123.64 on Monday. The firm has a market capitalization of $49.18 billion, a price-to-earnings ratio of 3.77, a price-to-earnings-growth ratio of 0.72 and a beta of 1.69. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.71 and a current ratio of 1.99. Moderna, Inc. has a one year low of $115.61 and a one year high of $453.61. The stock's fifty day moving average is $151.78 and its 200-day moving average is $150.86.
Moderna (NASDAQ:MRNA – Get Rating) last issued its quarterly earnings results on Wednesday, August 3rd. The company reported $5.24 EPS for the quarter, beating analysts' consensus estimates of $4.73 by $0.51. The company had revenue of $4.73 billion for the quarter, compared to analyst estimates of $3.95 billion. Moderna had a return on equity of 94.76% and a net margin of 61.12%. The company's quarterly revenue was up 8.7% compared to the same quarter last year. During the same period last year, the company earned $6.46 earnings per share. Equities analysts anticipate that Moderna, Inc. will post 26.41 EPS for the current year.Insider Activity
In related news, Director Noubar Afeyan sold 10,000 shares of Moderna stock in a transaction dated Wednesday, June 29th. The stock was sold at an average price of $140.47, for a total transaction of $1,404,700.00. Following the transaction, the director now directly owns 2,517,209 shares of the company's stock, valued at $353,592,348.23. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, CEO Stephane Bancel sold 40,000 shares of Moderna stock in a transaction dated Thursday, September 22nd. The stock was sold at an average price of $124.75, for a total transaction of $4,990,000.00. Following the transaction, the chief executive officer now directly owns 5,411,946 shares of the company's stock, valued at $675,140,263.50. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Noubar Afeyan sold 10,000 shares of Moderna stock in a transaction dated Wednesday, June 29th. The stock was sold at an average price of $140.47, for a total value of $1,404,700.00. Following the transaction, the director now directly owns 2,517,209 shares in the company, valued at $353,592,348.23. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 648,048 shares of company stock valued at $101,158,042. Company insiders own 17.30% of the company's stock.
Analyst Ratings Changes
MRNA has been the subject of several research analyst reports. Morgan Stanley reduced their target price on Moderna from $199.00 to $197.00 and set an "equal weight" rating for the company in a research note on Thursday, August 4th. Deutsche Bank Aktiengesellschaft upgraded Moderna from a "hold" rating to a "buy" rating and increased their target price for the company from $155.00 to $165.00 in a research note on Wednesday, September 7th. SVB Leerink increased their target price on Moderna from $70.00 to $77.00 and gave the company an "underperform" rating in a research note on Monday, August 1st. Finally, Argus reduced their price objective on Moderna from $180.00 to $150.00 and set a "buy" rating on the stock in a research note on Wednesday, September 14th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $211.08.
Moderna Profile
(Get Rating)
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.
Featured Stories
- Get a free copy of the StockNews.com research report on Moderna (MRNA)
- Can Caterpillar Claw Higher in a Falling Market?
- Is Dave & Buster's Immune to High Inflation and Lower Spending?
- Should These 3 Top-Performing Mid-Caps Be On Your Watchlist?
- Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
- MarketBeat: Week in Review 9/19 – 9/23
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.